“Two-for-one” cancer immunotherapy more effective and at least as safe as standard treatments

A “two-for-one” cancer immunotherapy is potentially more effective and at least as safe as standard immunotherapies, physician-scientists from UPMC Hillman Cancer Center who led an international, early-phase clinical trial report today in the journal Nature Medicine.

Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study

In a prelude to what is hoped will be regulatory approval of MDMA-assisted therapy in the U.S. and Canada, Numinus Wellness Inc. (TSE: NUMI) (OTCMKTS: NUMIF) has taken steps

June 15, 2023

Second round of inflation-related rebates hits 43 drugs from Amgen, Seagen, AbbVie and others

The Department of Health and Human Services on Friday revealed its latest round of coinsurance savings for seniors on drugs with prices rising faster than

June 9, 2023

IV Immunoglobulin May Cut Infection Risk of Anti-BCMA Agents for Myeloma

Use of intravenous immunoglobulin (IVIg) may substantially reduce the risk for severe infections in multiple myeloma patients treated with an anti-B-cell maturation antigen (BCMA) bispecific

September 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.